In:
Immunology & Cell Biology, Wiley, Vol. 90, No. 1 ( 2012-01), p. 130-134
Abstract:
The success of cancer immunotherapy is limited by potent endogenous immune‐evasion mechanisms, which are at least in part mediated by transforming growth factor‐ β (TGF‐β). The E3 ubiquitin ligase Cbl‐b is a key regulator of T cell activation and is established to regulate TGF‐β sensitivity. cblb ‐deficient animals reject tumors via CD8 + T cells, which make Cbl‐b an ideal target for improvement of adoptive T‐cell transfer (ATC) therapy. In this study, we show that cblb ‐deficient CD8 + T cells are hyper‐responsive to T‐cell receptor (TCR)/CD28‐stimulation and are in part protected against the negative cues induced by TGF‐β in vitro . Notably, adoptive transfer of polyclonal, non‐TCR transgenic cblb ‐deficient CD8 + T cells is not sufficient to reject B16‐ova or EG7 tumors in vivo . Thus, cblb ‐deficient ATC requires proper in vivo re‐activation by a dendritic cell (DC) vaccine. In strict contrast to ATC monotherapy, this approach delayed tumor outgrowth and significantly increased survival rates, which is paralleled by increased CD8 + T‐cells infiltration to the tumor site and enrichment of ova‐specific and interferon‐γ (IFN‐γ)‐secreting CD8 + T cell in the draining lymph node (LN). Moreover, CD8 + T cells from cblb ‐deficient mice vaccinated with the DC vaccine show increased cytolytic activity in vivo . In summary, our data using cblb‐ deficient polyclonal, non‐TCR‐transgenic adoptively transferred CD8 + T cells into immuno‐competent non‐lymphodepleted recipients suggest that targeting Cbl‐b might serve as a novel ‘adjuvant approach’, suitable to augment the effectiveness of established anti‐cancer immunotherapies.
Type of Medium:
Online Resource
ISSN:
0818-9641
,
1440-1711
Language:
English
Publisher:
Wiley
Publication Date:
2012
detail.hit.zdb_id:
2011707-3
SSG:
12
